Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07639086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

Study acronym: STOP-NEPC
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
Trial Details
NCT Number NCT07639086
Lead Sponsor Virginia Commonwealth University
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Related terms Disease Progression, Prostatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov